Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1

Pharmacogenetics and Genomics

Volumn 22, Issue 7, 2012, Pages 525-537

  Liu, Wen ^a   Poole, Elizabeth M ^b   Ulrich, Cornelia M ^b,c   Kulmacz, Richard J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

aspirin; cyclooxygenase; polymorphisms; prostaglandin H synthase 1

Indexed keywords

ACETYLSALICYLIC ACID; BACULOVIRUS VECTOR; CYCLOOXYGENASE 1; HOMODIMER; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEROXIDASE; PROSTAGLANDIN SYNTHASE;

AFFINITY CHROMATOGRAPHY; ARTICLE; CATALYSIS; CRYSTALLOGRAPHY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN PURIFICATION; THIN LAYER CHROMATOGRAPHY; THROMBOCYTE;

HEXAPODA;

EID: 84862762127     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835366f6     Document Type: Article

References (56)

1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56:387-437. (Pubitemid 39096597)
2. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007; 297:2018-2024. (Pubitemid 46740354)
3. Patrono C, Rocca B. Drug insight: aspirin resistance-fact or fashion? Nat Clin Pract Cardiovasc Med 2007; 4:42-50. (Pubitemid 44971071)
4. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6:130-140. (Pubitemid 43361545)
5. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41.
6. Rome LH, Lands WE. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975; 72:4863-4865.
7. DeWitt DL, el-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990; 265:5192-5198.
8. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry 1983; 22:4672-4675. (Pubitemid 13016991)
9. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56:624-632.
10. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2:637-643.
11. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3:2340-2345. (Pubitemid 41727215)
12. Ulrich CM, Bigler J, Sparks R, Whitton J, Sibert JG, Goode EL, et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13:889-893. (Pubitemid 38737881)
13. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29:308-311. (Pubitemid 32054478)
14. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209:130-139. (Pubitemid 24352000)
15. Lee CR, Bottone FG Jr, Krahn JM, Li L, Mohrenweiser HW, Cook ME, et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet Genomics 2007; 17:145-160.
16. Blobaum AL, Marnett LJ. Structural and functional basis of cyclooxygenase inhibition. J Med Chem 2007; 50:1425-1441. (Pubitemid 46564365)
17. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96:7563-7568. (Pubitemid 29299702)
18. Ren Y, Loose-Mitchell DS, Kulmacz RJ. Prostaglandin H synthase-1: evaluation of C-terminus function. Arch Biochem Biophys 1995; 316:751-757.
19. Ulrich CM, Bigler J, Sibert J, Greene EA, Sparks R, Carlson CS, et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20:409-410.
20. Rogge CE, Liu W, Kulmacz RJ, Tsai AL. Peroxide-induced radical formation at TYR385 and TYR504 in human PGHS-1. J Inorg Biochem 2009; 103:912-922.
21. Liu W, Poole EM, Ulrich CM, Kulmacz RJ. Polymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors. Pharmacogenomics J 2011; 11:337-347.
22. Peterson GL. Determination of total protein. Methods Enzymol 1983; 91:95-119.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680-685.
24. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 11:36-42.
25. Kulmacz R, Lands W. Cyclo-oxygenase: measurement, purification and properties. In: Benedetto C, McDonald-Gibson R, Nigam S, Slater T, editors. Prostaglandins and related substances: a practical approach. Washington DC: IRL Press. 1987. pp. 209-227.
26. Liu W, Cao D, Oh SF, Serhan CN, Kulmacz RJ. Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J 2006; 20:1097-1108. (Pubitemid 44943906)
27. Kulmacz RJ, Lands WE. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985; 260:12572-12578. (Pubitemid 16233460)
28. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22:3099-3108.
29. Gerngross O, Kersasp H. Salts of acetylsalicylic acid. Eur J Org Chem 1914; 406:240-260.
30. Choudhury S, Mitra AK. Kinetics of aspirin hydrolysis and stabilization in the presence of 2-hydroxypropyl-beta-cyclodextrin. Pharm Res 1993; 10:156-159. (Pubitemid 23020855)
31. Kulmacz RJ. Concerted loss of cyclooxygenase and peroxidase activities from prostaglandin H synthase upon proteolytic attack. Prostaglandins 1989; 38:277-288. (Pubitemid 19228782)
32. Salmon JA, Flower RJ. Extraction and thin-layer chromatography of arachidonic acid metabolites. Methods Enzymol 1982; 86: 477-493.
33. Bakar SK, Niazi S. Stability of aspirin in different media. J Pharm Sci 1983; 72:1024-1026. (Pubitemid 13003518)
34. Kulmacz RJ, van der Donk WA, Tsai AL. Comparison of the properties of prostaglandin H synthase-1 and-2. Prog Lipid Res 2003; 42:377-404. (Pubitemid 36694104)
35. Doyen JR, Yucer N, Lichtenberger LM, Kulmacz RJ. Phospholipid actions on PGHS-1 and-2 cyclooxygenase kinetics. Prostaglandins Other Lipid Mediat 2008; 85:134-143.
36. Capdevila JH, Morrow JD, Belosludtsev YY, Beauchamp DR, DuBois RN, Falck JR. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). Biochemistry 1995; 34:3325-3337.
37. Halushka MK,Walker LP, Halushka PV. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin Pharmacol Ther 2003; 73:122-130. (Pubitemid 36158493)
38. Shi J, Misso NL, Duffy DL, Bradley B, Beard R, Thompson PJ, et al. Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur Respir J 2005; 26:249-256. (Pubitemid 41079068)
39. Tsai AL, Kulmacz RJ. Prostaglandin H synthase: resolved and unresolved mechanistic issues. Arch Biochem Biophys 2010; 493:103-124.
40. Thuresson ED, Lakkides KM, Rieke CJ, Sun Y,Wingerd BA, Micielli R, et al. Prostaglandin endoperoxide H synthase-1: the functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J Biol Chem 2001; 276: 10347-10357.
41. Smith T, Leipprandt J, DeWitt D. Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and-2. Arch Biochem Biophys 2000; 375:195-200. (Pubitemid 30133639)
42. Kennedy TA, Smith CJ, Marnett LJ. Investigation of the role of cysteines in catalysis by prostaglandin endoperoxide synthase. J Biol Chem 1994; 269:27357-27364. (Pubitemid 24346559)
43. Zhou G, Marathe GK, Willard B, McIntyre TM. Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood. J Biol Chem 2011; 286:34820-34829.
44. Rance MJ, Jordan BJ, Nichols JD. A simultaneous determination of acetylsalicylic acid, salicylic acid and salicylamide in plasma by gas liquid chromatography. J Pharm Pharmacol 1975; 27:425-429.
45. Rowland M, Riegelman S, Harris PA, Sholkoff SD, Eyring EJ. Kinetics of acetylsalicylic acid disposition in man. Nature 1967; 215:413-414.
46. Davison C. Salicylate metabolism in man. Ann N Y Acad Sci 1971; 179:249-268.
47. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, et al. Association of cyclooxygenase-1-dependent and-independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120:2586-2596.
48. Perrone MG, Scilimati A, Simone L, Vitale P. Selective COX-1 inhibition: a therapeutic target to be reconsidered. Curr Med Chem 2010; 17:3769-3805.
49. Chan AT, Arber N, Burn J, Whay-Kuang Chia J, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2011; 5:164-178.
50. Agundez JA, Martinez C, Perez-Sala D, Carballo M, Torres MJ, Garcia-Martin E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab 2009; 10:998-1008.
51. Lee CR, North KE, Bray MS, Couper DJ, Heiss G, Zeldin DC. Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther 2008; 83:52-60.
52. Hahn T, Heinzel S, Plichta MM, Reif A, Lesch KP, Fallgatter AJ. Neurovascular coupling in the human visual cortex is modulated by cyclooxygenase-1 (COX-1) gene variant. Cereb Cortex 2011; 21:1659-1666.
53. Rosenstock M, Danon A, Rimon G. PGHS-2 inhibitors, NS-398 and DuP-697, attenuate the inhibition of PGHS-1 by aspirin and indomethacin without altering its activity. Biochim Biophys Acta 1999; 1440:127-137. (Pubitemid 29406156)
54. Rosenstock M, Danon A, Rubin M, Rimon G. Prostaglandin H synthase-2 inhibitors interfere with prostaglandin H synthase-1 inhibition by nonsteroidal anti-inflammatory drugs. Eur J Pharmacol 2001; 412:101-108. (Pubitemid 32149774)
55. Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98:14583-14588. (Pubitemid 33121435)
56. Rimon G, Sidhu RS, Lauver DA, Lee JY, Sharma NP, Yuan C, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 2010; 107:28-33.